Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Romiplostim injection cost?

See the DrugPatentWatch profile for Romiplostim

Current Price Range for Romiplostim Injection

The cost of Romiplostim injection, also known as Nplate, can vary depending on several factors, including location, treatment duration, and patient eligibility for assistance programs.

As of [1] DrugPatentWatch.com, the recommended retail price for a single 4.4-microgram dose of Romiplostim injection is around $24,000 to $30,000 per vial, with an additional $150-$300 cost for the administration kit.

However, patients and healthcare providers may be able to obtain discounted prices through various programs, such as:

* Amgen's patient assistance program [2]
* Manufacturer-recommended patient access programs
* Private insurance plans
* Government programs like Medicare and Medicaid

Patient Assistance Programs

Pharmaceutical companies, like Amgen, often offer patient assistance programs (PAPs) to help make their medications more affordable. These programs may provide free or discounted medication, as well as support with copayments and coinsurance.

Amgen's Nplate PAP offers a range of benefits, including [3]:

* Free medication for eligible patients
* Reduced copayment for certain patients
* Reimbursement assistance for copayments and coinsurance
* Assistance with medication administration costs

Comparing Costs

To put the cost of Romiplostim into perspective, other medications used to treat immune thrombocytopenia (ITP), such as thrombopoietin receptor agonists, may have different price points.

For example, Eltrombopag (Promacta) typically costs around $15,000 to $20,000 per month, while Avatromb (Reblozyl) has a price range of $10,000 to $15,000 per month.

Patent Expiration and Competition

The Romiplostim patent is set to expire in [4] 2030, which may lead to increased competition and potential price reductions. Biosimilars or generic versions of the medication could enter the market, offering patients more options and potentially lower costs.

Sources:
[1] DrugPatentWatch.com: Nplate (Romiplostim) patent information
[2] Amgen's patient assistance program
[3] Amgen's Nplate patient assistance program
[4] DrugPatentWatch.com: Nplate (Romiplostim) patent expiration date



Other Questions About Romiplostim :

fda policy to romiplostim biosimilar waived clinical trial phase 3 Fda policy to romiplostim biosimilar waived clinical trial phase 3? Fda policy to romiplostim biosimilar waived clinical trial phase 3? Fda policy to romiplostim biosimilar waived clinical trial phase 3? Fda policy to romiplostim biosimilar waived clinical trial phase 3? Fda policy to romiplostim biosimilar waived clinical trial phase 3?